Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : 100% + Gain, in 72 Hours or Less -- Ignore unavailable to you. Want to Upgrade?

To: Just-a-thought who wrote (987)	3/5/1998 11:28:00 AM
From: buckman	Read Replies (3) \| Respond to of 1488

The NEXT 100%+ Gainer...... This one is still undiscovered by the momentum players... Currently trading around $0.33, 3 million float with most shares held by insiders at an average price of $1.19 BGIX just came out with their product update that blows away the competition (STAT) and (DMED). STAT currently trading at $16.00 and DMED at $5.75. More news coming soon concerning their Virtual Hospital Biologix International's Blood-Gas Analyzer Beats Competition; The EPOC System(TM) Shatters Two-Minute Results Barrier PR Newswire - March 04, 1998 13:43 SAN FRANCISCO, March 4 /PRNewswire/ -- Biologix International, Ltd. (OTC Bulletin Board: BGIX), the first company in the world to introduce the concept of the hand-held blood/gas analyzer to the point-of-care industry, announced today that the biosensors for its fledgling product, The EPOC System(TM), return results of ph, carbon dioxide, oxygen and bicarbonate analysis in five seconds or less, well ahead of the industry's two-minute standard. Biologix also stated today that based on manufacturing estimates, the EPOC system also will be produced at lower cost than its competition. The EPOC System's high volume/low cost processes will employ only 20 authenticated steps to produce the product, which is significantly fewer than the industry norm and will directly reduce overall costs to the end-user. Biologix predicts that its fully burdened cost of goods sold will yield only a $1,200 retail price. Average competitor prices are currently in excess of $3000 per unit. "We expect to piggyback FDA certification, under form 51OK, based on substantial equivalency in the near term," stated Michael Grandon, Chairman of Biologix International, Ltd. "Once approved, we will either sell and/or license our product depending on prevailing market conditions." Recent published reports including a Forbes article (March 9, 1998, pg. 208), confirm that such Biologix competitors as Nova Biomedical, I-Stat Corp. (OTC Bulletin Board: STAT) and Diametrics Medical (Nasdaq: DMED), all have portable blood analyzers on the market that return blood results in approximately two minutes. In recent news, on December 22, 1997, Biologix announced that it had entered into a joint venture with Menlo Park, CA-based Microbionics, Inc. to develop medical diagnostic biosensors. Microbionics holds some of the world's most advanced biosensor patents and currently has strategic alliances with the NASA-Ames "Sensor 2000!" program and The Center for Industrial Sensors and Measurements at Ohio State University. EPOC stands for Emergency Point Of Care. The EPOC System is designed on an innovative and modular basis so that its basic hand-held diagnostic instrument serves as a portable platform for performing a wide-range of blood chemistry and blood gas analysis tests utilizing a variety of proprietary disposable cartridges. Its presented analysis speed of less than five seconds and less than one second for some test parameters positions the product perfectly for the "Point of Care" markets, which include emergency medical services, fire and rescue, military response as well as emergency rooms.